Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04435665 · ClinicalTrials.gov registry record · Phase 2
NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
A Phase 2 study, sponsored by NFlection Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT04435665 is a Phase 2 study that has completed, run by NFlection Therapeutics. The registered enrollment target is 48 participants.
The verdict
NCT04435665, a Phase 2 study, has completed, sponsored by NFlection Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study will enroll and treat subjects with cutaneous neurofibromas with NFX-179, a topical study drug. Eligible subjects will receive treatment for 28 days and be observed by a study doctor for approximately 56 days. Subjects will be randomly assigned to 1 of 4 treatment groups. 3 of the treatment groups will receive a specific dose NFX-179, and 1 group will receive placebo. The subject, study doctor, and NFlection Therapeutics will not know what treatment group each subject is assigned. Study participation requires at least 7 clinic visits, blood, urine, and tissue collection, images of the treated cutaneous neurofibromas, electrocardiograms, and information regarding the subject's medical and disease history.
Interventions
- DRUG Vehicle Gel
- DRUG NFX-179 Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-08-21 |
| Est. Completion | 2021-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04435665
The ClinicalTrials.gov registry entry for NCT04435665 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NFlection Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Gel is the first listed.
NCT04435665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04435665 about?
NCT04435665 is a clinical study titled "NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)". This study will enroll and treat subjects with cutaneous neurofibromas with NFX-179, a topical study drug. Eligible subjects will receive treatment for 28 days and be observed by a study doctor for approximately 56 days. Subjects will be randomly assigned to 1 of 4 treatment groups. 3 of the treatme...
What is the current status of trial NCT04435665?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-08-21. Estimated completion is 2021-04-14.
What interventions are being tested in trial NCT04435665?
The interventions under investigation include: Vehicle Gel (DRUG), NFX-179 Gel (DRUG).
Who is sponsoring clinical trial NCT04435665?
This trial is sponsored by NFlection Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.